<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GEFITINIB <img border="0" src="../images/pr.gif"/></span><br/>(ge-fi'ti-nib)<br/><span class="topboxtradename">Iressa<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">epidermal growth factor receptor (egfr)</span>; <span class="classification">tyrosine kinase inhibitor</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI). EGFR is expressed or
         overexpressed in many cancers. EGFR expression is associated with poor prognosis, development of metastasis, and resistance
         to chemotherapy, hormonal therapy, and radiation therapy.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Gefitinib inhibits up-regulation or overexpression of EGRF in cancer cells diminishing their capacity for cell proliferation,
         cell survival, and decreasing their invasive capacity and metastases.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of locally advanced or metastatic non-small cell lung cancer after failure of both platinum and docetaxel therapy
         in patients who have previously used gefitinib.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of head and neck and other solid tumors.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to gefitinib; pregnancy (category D), lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Severe renal impairment; hepatic impairment; bacterial/viral infection; dermatologic toxicities; GI disorders; hepatic insufficiency;
         interstitial lung disease (interstitial pneumonia, pneumonitis, and alveolitis), pulmonary fibrosis, respiratory insufficiency;
         myelosuppression; females of childbearing age; prior chemotherapy, radiation therapy; ocular toxicities (corneal ulcer, eye
         pain).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Non-Small Cell Lung Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q.d., may increase to 500 mg q.d. if on enzyme-inducing drugs<br/><br/><span class="indicationtitle">Head and Neck Cancers</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to meals.</li>
<li>Store tablets at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, peripheral edema. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea, vomiting,</span> anorexia, weight loss, stomatitis. <span class="typehead">Respiratory:</span> Dyspnea, <span class="speceff-life">interstitial lung disease.</span>
<span class="typehead">Skin:</span>
<span class="speceff-common">Acne/acneiform rash, dry skin,</span> pruritus, vesicular/bullous rash. <span class="typehead">Special Senses:</span> Amblyopia, conjunctivitis, aberrant eyelash growth. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">barbiturates</span>, <b>bosentan, carbamazepine, dexamethasone, nevirapine, oxcarbazepine, phenytoin or fosphenytoin, rifampin, rifabutin, rifapentine</b> may increase metabolism and decrease levels of <b>gefitinib; amiodarone,</b>
<span class="classification">protease inhibitors</span>, <b>cimetidine, clarithromycin, dalfopristin; quinupristin, delavirdine, efavirenz, erythromycin, fluconazole, fluvoxamine, fluoxetine,
         imatinib, itraconazole, ketoconazole, mifepristone, nefazodone and voriconazole</b> may increase levels and toxicity of gefitinib; may increase INR with <b>warfarin;</b>
<span class="classification">h<sub>2</sub>-receptor antagonists</span>, <span class="classification">proton pump inhibitors</span> may decrease absorption of gefitinib. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> may increase levels and toxicity of gefitinib. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease levels of <b>gefitinib.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed, 60% reaches systemic circulation. <span class="typehead">Peak:</span> 37 h. <span class="typehead">Metabolism:</span> Metabolized in liver primarily by CYP3A4. <span class="typehead">Elimination:</span> 86% eliminated in feces. <span class="typehead">Half-Life:</span> 48 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor pulmonary status and report promptly dyspnea, cough, and fever.</li>
<li>Withhold drug and notify physician for significant elevations of transaminases, bilirubin, or alkaline phosphatase.</li>
<li>Monitor for adverse effects, especially with concurrent use of drugs that may inhibit CYP3A4 (e.g., amiodarone, cimetidine,
            erythromycin, fluconazole, grapefruit juice, etc.). See <small>INTERACTIONS</small>.
         </li>
<li>Lab tests: Periodic LFTs; frequent PT/INR with concurrent warfarin.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following: eye pain or irritation; fever; breathing difficulty or shortness of breath; mouth sores.</li>
<li>Inform physician of all prescription, nonprescription, or herbal drugs you are taking.</li>
<li>Females should use reliable contraceptives while taking this drug.</li>
<li>Minimize or avoid intake of grapefruit juice while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>